Literature DB >> 309489

Regulation of antibody response in different immunoglobulin classes. V. Establishment of T hybrid cell line secreting IgE class-specific suppressor factor.

T Watanabe, M Kimoto, S Maruyama, T Kishimoto, Y Yamamura.   

Abstract

Establishment of a mouse T hybrid cell line secreting suppressor factor(s) specific for the IgE antibody response is described. Fusion was made with polyethyleneglycol between AKR-derived T lymphoma cells (BW5147) and T cells from mice sensitized with DNP-Mycobacterium. Treatment of spleen cells with nondialyzable factor(s) in the culture supernatants of the T cell hybrid clone, 26-M10, showed a suppressive effect on IgE formation but not on IgG formation in adoptive transfer experiments. The suppressive effect was exerted through inactivation of normal or antigen-primed B cells responsible for IgE formation. It was also shown by direct cytotoxic test that the hybrid cells expressed H-2 and Thy-1 antigens derived from both parental cells on their surface. Karyotype analysis of the hybrid cells revealed that the number of chromosomes was less than the sum of the two parental cells' and the average was 50 (45 to 55). Although the 26-M10 hybrid cells lost the ability to secrete active suppressive factor(s) into culture medium 21 weeks after hybridization when the number of chromosomes in most of the cells was less than 41, recloning of the 26-M10 cells successfully recovered active suppressive clones.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309489

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  T lymphocytes emigrating from the thymus to the spleen during postpartum regulate serum immunoglobulin levels in mice.

Authors:  M Yokoyama; Y Koga; K Taniguchi; H Nakano; K Nomoto
Journal:  Immunology       Date:  1988-01       Impact factor: 7.397

2.  Production of bovine immunoregulatory molecules by xenogeneic hybrids.

Authors:  R A Collins; B V Jones; G Oldham
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

Review 3.  Recent studies on the regulation of IgE antibody synthesis in experimental animals and man.

Authors:  D H Katz
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

4.  T-cell hybridomas producing hapten-specific suppressor factors.

Authors:  S Kontiainen; E J Culbert; M Cecka; E Simpson; I F McKenzie; M Feldmann
Journal:  Immunology       Date:  1981-08       Impact factor: 7.397

5.  Hyper IgM immunodeficiency. A primary dysfunction of B lymphocyte isotype switching.

Authors:  D Levitt; P Haber; K Rich; M D Cooper
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

6.  Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules.

Authors:  M Okada; N Yoshimura; T Kaieda; Y Yamamura; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

7.  T-cell hybridoma co-expressing Fc receptors for different isotypes. I. Reciprocal regulation of Fc alpha R and Fc gamma R expression by IgA and interferon.

Authors:  J Yodoi; M Adachi; K Teshigawara; T Masuda; W H Fridman
Journal:  Immunology       Date:  1983-03       Impact factor: 7.397

8.  Suppressor factor from a T cell hybrid inhibits delayed-type hypersensitivity responses to azobenzenearsonate.

Authors:  R B Whitaker; J T Nepom; M S Sy; M Takaoki; C F Gramm; I Fox; R N Germain; M J Nelles; M I Greene; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

9.  Selective suppression of the major idiotypic component of an antihapten response by soluble T cell-derived factors with idiotypic or anti-idiotypic receptors.

Authors:  Y Hirai; A Nisonoff
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  A clonal analysis of the IgE response and its implications with regard to isotope commitment.

Authors:  J M Teale; F T Liu; D H Katz
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.